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Background: Special AT-rich sequence binding protein 1 (SATB1) is found acting as a “genome organizer” that
functions as a landing platform to regulate tissue-specific gene ex-pression. In breast cancer cell lines it has been
proven that SATB1 could upregulate the expression of the HER2. In this paper, the relevance of SATB1 and HER2
expression was assessed in human breast cancer tissues, and their influence on tumor histological grade and
patients’ survival was explored.
Methods: Using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), 169 patients with breast
cancer were assessed for SATB1 expression, HER2 amplification and hormone-receptor (HR) expression. The effects
of SATB1 expression on HER2 and HR expression as well as their association with clinicopathologic characteristics
were further analyzed by statistical evaluation.
Results: SATB1 expression was correlated with HER2 expression in breast cancer(r = 0.191; p = 0.013). SATB1, HER2
and SATB1/HER2 co-expression was negatively correlated with HR expression (r = −0.228, p = 0.003; r = −0.338,
p = 0.000; r = −0.527, p = 0.000, respectively). SATB1 and HER2 single positive and their co-expression were all
significantly correlated with higher histological grade (r = 0.239, p = 0.002; r = 0.160, p = 0.038; r = 0.306, p = 0.003,
respectively). Multivariate cox regression analyses showed that SATB1 and HER2 were independent risk factors for
breast cancer patients, while HR was a protective factor for patients’ survival. Comparing to SATB1 or HER2 single
positive expression, SATB1/HER2 co-expression tended to have even worse prognosis.
Conclusions: SATB1 and HER2 performed a synergistic effect in breast cancer. Their expression correlated with
poorly differentiated breast cancer and indicated an unfavorable prognosis.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1400555050159723.
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Special AT-rich sequence binding protein 1 (SATB1) has
been shown to regulate the expression of more than ten
percent of genes by binding to the upstream regulatory
regions which directly influence the promoter activity
and gene expression [1-3]. SATB1 is reported to carry* Correspondence: sdjnwys@hotmail.com
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unless otherwise stated.important weight to the progression of gastric cancer,
cutaneous malignant melanoma, breast cancer, lung can-
cer, and lymphoma [4,5,3,6,7]. A large number of target
genes regulated by SATB1 involve in cancer cell prolifer-
ation, development and differentiation. Han et al. [3]
showed that SATB1 protein was detected in all 16 poorly
differentiated infiltrating ductal breast carcinomas, and
the human epidermal growth factor receptor 2 (HER2)
gene was directly upregulated by SATB1.s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Relationships between the expression status of
SATB1, HER2 and HR and clinicopathologic parameters
Parameter n SATB1 HER2 HR
+ - P + - P + - P
Age
≤50 76 40 36 0.672 23 53 0.26 48 28 0.97
>50 93 52 41 21 72 59 34
Tumor size
≤2 cm 45 22 23 0.386 10 35 0.499 29 16 0.855
>2 cm 124 70 54 34 90 78 46
Tumor type
IDC 144 79 65 0.538 37 107 0.214 90 54 0.879
ILC 13 6 7 5 8 9 4
Others 12 7 5 2 10 8 4
Histological grade
Low 56 21 35 0.002 9 47 0.038 39 17 0.232
High 113 71 42 35 78 68 45
Lymph node status
Negative 78 42 36 0.887 19 59 0.648 45 33 0.162
Positive 91 50 41 25 66 62 29
TNM stage
I-II 118 61 57 0.279 26 92 0.072 77 41 0.429
III-IV 51 31 20 18 33 30 21
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oncogenic protein with tyrosine kinase activity. Phosphoryl-
ation of HER2 could trigger downstream signaling events
involved in malignant transformation and tumorigenesis,
and ultimately result in poor clinical outcomes [8,9].
As a hormone-dependent tumor, ascertainment of
estrogen-receptor (ER) and progesterone-receptor (PR)
along with HER2 is regarded essential to treatment of
breast cancer [10,11]. It is reported that positive expres-
sion of hormone-receptor (HR, including ER and/or PR)
generally carries a better prognosis, on account of the
target of response to endocrine therapy [9,11]. As a pre-
dictive marker, HER2 amplification values high in HER2
targeting therapy. In addition, the amplification of HER2
played a negative role in responding to endocrine sensi-
tivity in recent discovery; over-expression of HER2
might lead to resistance to tamoxifen therapy [12]. Thus,
the interaction between HER2 and HR is probably di-
rected by complex mechanisms.
In breast cancer progression, Ras/Raf/MEK/MAPK
and PI3K/Akt/mTOR signaling pathways are commonly
dysregulated by the crosstalk among various growth fac-
tors and hormone receptors including HER2 and ER
[13]. Several experimental studies demonstrate that the
activation of these two signaling pathways by HER2 lead
to phosphorylation and activation of ERα [14]. Shigeaki
Kato et al. [14] reported that MAPKs could be activated
through EGF-HER2 signaling pathway and the activated
MAPK was able to phosphorylate the Ser 118 of ERα.
PI3K signaling pathway, which is a major signaling hub
downstream of HER2 and other receptor tyrosine ki-
nases, could promote anti-estrogen resistance [15].
Herein, HER2 can alter ER’s function and thereby con-
tribute to tumor growth and tamoxifen resistance ac-
cording to the signaling crosstalk between ER and HER2
pathways. Interestingly, Han et al. [3] reported that
MAPK signaling was activated and PI3K/mTOR signal-
ing was suppressed by SATB1 in breast cancer cells.
Therefore, the association among SATB1, HER2 and HR
in breast cancer is still confounded.
Previous studies have demonstrated that HR expression
correlated with low histological grade, while HER2 expres-
sion correlated with high histological grade in breast cancer
[10,16]. It was reported that the expression of SATB1 was
higher in poorly differentiated than in well differentiated
breast cancer and completely absent in adjacent normal tis-
sues [3,17]. But to our knowledge, little information has
been available on the relationships among the expression of
SATB1, HER2 and HR in breast cancer tissues so far.
The objectives of this study were to assess the correla-
tions of SATB1 expression with HER2 and HR expression
in breast cancer tissues, and to evaluate the effects of
SATB1 expression on HER2 and HR expression as well as
their relationships with clinicopathologic characteristics.Methods
Patients and tissue samples
169 breast cancer patients from Jinan Central Hospital Af-
filiated to Shandong University and Shandong Province
Key Laboratory for Tumor Target Molecule (China),
treated with surgical resection between January 2000 and
December 2010, were studied in this paper. All the indi-
viduals were treatment-naive before pathologically identi-
fied as breast cancer. Ethical permission was obtained
from the Ethics Committee in Jinan Central Hospital. We
got all patients’ informed consent prior to their inclusion
in our study. The patients were all females and aged 29–
81 years (mean 53.6 years). The median follow-up period
was 95 months with a range of 2–131 months. Tissue
samples were divided into two groups: breast cancer tis-
sues samples (n = 169) and corresponding paracancerous
normal tissue samples (n = 40). Survival data was available
in 119 patients. All cancers were histopathologically con-
firmed as invasive ductal carcinoma (IDC) (n = 144), inva-
sive lobular carcinoma (ILC) (n = 13) and other types (n =
12). Histological grade was classified according to Elston/
Nottingham modification of the Bloom-Richardson system
[18]. The clinicopathologic variables of the patients were
shown in Table 1.
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All specimens were fixed in neutral 10% buffered for-
maldehyde, embedded in paraffin, cut into 4-μm-thick
slices, and supplied for IHC and FISH test. Immunohisto-
chemistry (IHC) was used to determine SATB1 expression.
Rabbit monoclonal anti-SATB1 antibodies bought from
Abcam (Code ab92307, Abcam, USA) were used to analyze
the expression of SATB1 following the manufacturer’s in-
structions. Briefly, antigen retrieval was performed before
staining; anti-SATB1 antibody was diluted by 1:100 and in-
cubated overnight. After the samples were fully washed, the
polymer detection system (PV-9000, ZSGB-BIO, China)
was used for IHC staining. Sections were incubated with
the secondary polyperoxidase-anti-rabbit IgG antibody, and
chromogen substrate reagent DAB were used to detect the
antigen. A brown color reaction with distinct morphology
was developed with DAB in the peroxidase system. Positive
controls were processed using positive specimens which
were recommended by manufacturer’s instructions, and
negative controls were executed in parallel slices to which
the primary antibody were omitted [19].
The staining intensity and the percentage of stained
cancer cells were analyzed for SATB1 evaluation. The in-
tensity of the staining was scored as 0 (negative), 1
(weak), 2 (moderate) and 3 (strong). Semi-quantitative
grades were determined to assess the percentage of
stained cancer cells: 0 (<5% stained cells), 1 (5–25%
stained cells), 2 (25–50% stained cells) and 3 (>50%Figure 1 SATB1 expression by IHC(a-c, ×200) and HER2 amplification by FI
stained in the infiltrating lymphocytes but negatively stained in breast canc
HER2; F Amplification of HER2.stained cells). The sum of intensity and percentage was
calculated, which varied from 0 to 6. Scores of 0–2 were
regarded as negative expression, and others with scores
3–6 were defined as positive expression [4]. SATB1
expressed in the infiltrating lymphocytes were not
regarded as SATB1 positive for breast cancer cells
(Figure 1B).
HER2 evaluation
The breast cancer Fluorescence in Situ Hybridization
Testing Kit (Beijing GP Medical Technologies, Ltd,
China) was used to detect amplification of the HER2
gene. Experiments were carried out according to the
manufacturer’s recommendations. In brief, the slices
were deparaffinized in xylene, digested by protease, fixed
in neutral buffered formalin and denatured in the kit so-
lution. Then, hybridization procedure was carried over-
night (12–16 h) at 37°C using reagents containing the
HER2 DNA probe and the CEP17 DNA probe mixture.
After that, the slices were washed in washing buffer
and counterstained with 4′, 6-diamidino-2-phenylindole
(DAPI) in antifade solution. The slides were stored in
dark before signal enumeration. A minimum of 60
tumor cell nuclei were analyzed using a Nikon E-600
fluorescence microscope (Olympus, Japan) equipped
with DAPI, FITC and Rhodamine bandpass filters. To
rule out false-positive or false-negative results, the posi-
tive and negative control tissues were processed togetherSH(d-e, ×1000). A Negative SATB1 expression; B SATB1 was positively
er cells; C Positive SATB1 expression; D and E Non-amplification of
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on different tissue slides.
HER2 was quantified using the ratio of HER2 to
CEP17 signal counts according to the American Society
of Clinical Oncology (ASCO)/College of American Pa-
thologists (CAP) clinical practice guideline [20,21].
HER2 gene amplification was defined as the HER2/
CEP17 signal ratio > 2.0.
Hormone receptor test
The expression of ER and PR was determined in paraffin-
embedded tissue specimens by IHC technique similar to
SATB1. Mouse monoclonal anti-human ER and anti-
human PR (DKT-3011, MaiXin, China) were used to exam-
ine ER and PR protein expression status according to the
manufacturer’s instructions.
The expression of ER or PR was designated as positive
when more than 1% of tumor cells showed positive nu-
clear staining per 10 high-power fields, and others were
negative expression [22]. ER positive (ER+) and/or PR
positive (PR+) were defined as HR positive (HR+),
whereas ER and PR simultaneously negative expression
(ER-/PR-) was regarded as HR negative (HR-).
Statistical analyses
Statistical analyses were performed using SPSS 16.0
software (SPSS Inc., Chicago, IL, USA). The two-tailed
Chi-squared test or Fisher’s exact test and Spearman’s
correlation coefficient were used to evaluate the differ-
ences between the expression status of SATB1, HER2,
HR and clinicopathologic characteristics in breast cancer
patients. Survival curves were calculated using the
Kaplan–Meier method and compared by the log-rank
test. Univariate and multivariate Cox proportional-
hazard analyses were used to explore the effects of
SATB1/HER2/HR expression on patients’ survival [4].
p <0.05 was regarded as statistically significant.
Results
Expression of SATB1, HER2 and HR and their correlations
to clinicopathologic parameters in breast cancer tissues
To analyze SATB1 expression status in breast cancer
tissues and in corresponding paracancerous normal tis-
sues, SATB1 IHC analysis was performed (Figure 1).
SATB1 expression ratio (54.4%, n = 92) in cancer sam-
ples was significantly higher than that (17.5%, n = 7) in
corresponding paracancerous normal samples (χ2 =
17.701, p = 0.000). This result was similar to previous
studies [3,17]. Interestingly, our results showed that
SATB1 was expressed in the infiltrating lymphocytes
within some breast cancer tissues but not in the adjacent
non-malignant tissues. To examine HER2 expression
status in breast cancer tissues, HER2 FISH analysis was
performed (Figure 1). HER2+ expression was observedin 26.0% (n = 44) of the breast cancer samples, but HER2
amplification was not found in normal samples. These
results were also similar to previous studies [23].
Table 1 showed the relationships between the expression
status of SATB1, HER2 and HR and clinicopathologic char-
acteristics in patients with breast cancer, respectively. Ac-
cording to correlation analysis, the expression of SATB1
was associated with higher histological grade in patients
with breast cancer (r = 0.239, p = 0.002). Similar to SATB1,
HER2 was statistically associated with higher histological
grade (r = 0.160, p = 0.038). No association existed between
HR expression and histological grade (r = −0.092, p =
0.232). No relevance was observed between the expression
of SATB1, HER2 or HR with age, tumor size, tumor type,
lymph node status and TNM stage (p > 0.05 for each).
Relevance of SATB1 expression to HER2 amplification and
the relationship between their co-expression and breast
cancer histological grade
Analysis of the relevance of SATB1 and HER2 showed that
33.7% (n = 31) of samples were HER2+ in 92 SATB1+
samples, and that 70.5% (n = 31) of samples were SATB1+
in 44 HER2+ samples, but 16.9% (n = 13) were HER2+ in
77 SATB1- samples. A significant correlation was found
between SATB1 expression and the HER2 status (r =
0.191, p = 0.013).
Co-expression of SATB1 and HER2 was correlated with
higher histological grade (r = 0.306, p = 0.003). The per-
centage of higher histological grade increased progressively
with the status of SATB1 and HER2 expression: SATB1-/
HER2-, SATB1-, HER2-, SATB1-/HER2+, SATB1+/HER2-,
SATB1+, HER2+, SATB1+/HER2+ (Figure 2).
Association of SATB1/ HER2 expression with HR expression
Among 169 breast cancer tissues, ER+ and PR+ were
observed in 60.4% (n = 102) and 53.3% (n = 90) samples,
respectively, and HR+ was found in 63.3% (n = 107) sam-
ples. The HR- expression ratio in SATB1-, HER2- and
SATB1-/HER2- samples was similar (Figure 3A). On the
contrary, the percentage of HR- expression was gradually
elevated in SATB1+, HER2+ and SATB1+/HER2+ tis-
sues (Figure 3B). Compared to a large proportion of HR-
expression in SATB1/HER2 double positive status, HR+
expression ratio was remarkably lower (Figure 3C and
D). In addition, HR- and HR+ sample percentages varied
with different SATB1/HER2 status as shown in Figure 3C
and D. The results indicated that SATB1 and HER2 co-
expression could increase HR- expression ratio.
Similar to previous studies [16], HR- expression was sig-
nificantly higher in HER2+ samples compared with HER2-
samples (χ2 = 25.405, p = 0.000), and HR- expression was
as well increased significantly in SATB1+ samples com-
pared with SATB1- samples (χ2 = 8.785, p = 0.003). SATB1
and HER2 expression was negatively correlated with HR
Figure 2 The percentage of high tumor histological grade increased with different expression status of SATB1 and HER2 in breast cancer. The
percentage of higher histological grade increased progressively with the status of SATB1 and HER2 expression: SATB1-/HER2-, SATB1-, HER2-,
SATB1-/HER2+, SATB1+/HER2-, SATB1+, HER2+, SATB1+/HER2+.
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spectively). Furtherer, a significantly negative correlation
was observed between double positive expression of
SATB1/HER2 and HR expression (r = −0.527, p = 0.000)
(Figure 3E).Analyses of the prognostic value of SATB1, HER2 and HR
expression in breast cancer
It was described in our results above that SATB1 or HER2
single positive expression correlated with tumor histo-
logical grade. Moreover, SATB1/HER2 co-expression was
also significantly associated with higher tumor histological
grade (r = 0.306, p = 0.003). As shown in Figure 2, the per-
centage of higher histological grade samples increased ac-
cording to different SATB1 or HER2 status and reached to
peak level when SATB1 and HER2 were co-expressed.
The effect of SATB1 and HER2 expression on breast can-
cer patients’ survival time was assessed by Kaplan–Meiermethod. Results showed that patients with SATB1 positive
expression had a significantly lower survival rate than those
with negative expression (log-rank test, χ2 = 11.324, p =
0.001) (Figure 4A). Similar result was found in HER2 posi-
tive patients (χ2 = 12.486, p = 0.000) (Figure 4B). Compared
to SATB1 or HER2 single positive and SATB1 and HER2
double negative expression, SATB1/HER2 co-expression
was prone to have a worse prognosis (Figure 4C). HR ex-
pression showed an opposite tendency that HR positive ex-
pression inclined to acquire longer survival time (χ2 =
16.893, p = 0.000) (Figure 4D). Multivariate Cox regression
analyses showed that SATB1, HER2 and HR were inde-
pendent factors for survival rate in breast cancer (Table 2).
SATB1 positive patients were liable to have a worse prog-
nosis and the risk exposure was approximately 2.413 times
higher (95.0% CI: 1.197-4.846) than that in SATB1 negative
patients. Similarly, HER2 positive patients had 2.089 times
higher risk (95.0% CI: 1.100-3.969) to a grim prognosis. On
the contrary, HR was determined as a protective factor, and
Figure 3 Correlations between the expression status of SATB1/HER2 and HR expression. A 24.7% (n = 19) samples showed HR- in 77 SATB1- samples,
25.6% (n = 32) samples showed HR- in 125 HER2- samples, and 17.5% (n = 11) samples were HR- in 63 SATB1-/HER2- samples. B HR- expression was
found in 46.7% (n= 43) of 92 SATB1+ samples, 68.2% (n = 30) of 44 HER2+ samples, and 71.0% (n = 22) of 31 SATB1+/HER2+ samples, respectively. C
The effects of SATB1 and HER2 expression status on HR- expression. D The effects of SATB1 and HER2 expression status on HR+ expression. E SATB1/
HER2 co-expression was negatively correlated with HR expression in breast cancer (r = −0.527, p = 0.000).
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breast cancer (95.0% CI: 0.213-0.741).
Discussion and conclusions
Human breast cancer is the most malignancy in women
and is characterized by multitudinous genetic alterations
[24]. SATB1 is found acting as a “genome organizer” that
functions as a landing platform to regulate tissue-specific
gene expression [25]. Aberrant expression of SATB1 in
breast cancer cell lines can make rapid, major changes in
gene expression pattern which could alter the cells’ cancer-
ous phenotype [3,26]. Elimination of SATB1 in highly ag-
gressive cancer cell lines alters a large number of gene
expression and restrains tumor progress. On the contrary,
breast cancer cell lines with ectopic expression of SATB1experience great changes in their gene expression profile
and develop a metastatic phenotype [3]. Our study found
that the expression of SATB1 was associated with higher
histological grade in patients with breast cancer and SATB1
positive expression had a significantly lower survival rate
than those with negative expression. The result was consist-
ent to recent research reported by Heubner, whose work
revealed a SATB1 haplotype demonstrating lower activity
of SATB1 promotor, and this haplotype associated with im-
proved prognosis [27].
Among expression profile upregulated by SATB1, HER2
is an important regulator to breast cancer progression
[3,19]. HER2, a proto-oncogene localized on chromosome
17, is amplified and/or the protein overexpressed in 15-
25% of invasive breast cancer [16]. HER2 amplification in
Figure 4 Effects of the expression of SATB1, HER2 and HR to patients’ survival time in breast cancer by Kaplan–Meier analysis. A Overall survival
for patients with positive SATB1 expression was significantly lower than that with negative expression (SATB1 positive vs SATB1 negative,
p = 0.001). B Overall survival for patients with positive HER2 was significantly lower than that with negative expression (HER2 positive vs HER2
negative, p = 0.000). C SATB1/HER2 co-expression showed the worst prognosis. D Patients’ overall survival with positive HR was significantly higher
than that with negative expression (HR positive vs HR negative, p = 0.000).
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ness, tumourigenicity and worse clinical outcomes [28].
What’s more, HER2, as a specific target, could predict the
responsiveness to the monoclonal antibody treatment [29].
Thus, HER2 amplification status has become an increas-
ingly important and reliable predictor of patients’ treat-
ment and outcome. In this study, we identified that SATB1
protein expression was associated with HER2 amplification
in breast cancer tissues. As has been confirmed, SATB1
could directly upregulate HER2 amplification. Through a
series of successive regulation of SATB1 and HER2, the
breast cancer performed more malignant activities. How-
ever, we also found samples with SATB1-/HER2+ andSATB1+/HER2- expression patterns. This phenomenon
reflected that HER2 was not always modulated by SATB1.
Some other regulated factors also functioned, such as
Chromosome17 polysomy [23,30].
The hormone receptors play an important role in the
pathogenesis in breast cancer. By binding with estrogen-
responsive elements in the genome, they recruit a series of
cofactors that facilitate gene transcription [31]. Conse-
quently, they were regarded as effective target to endo-
crine therapy. However, recent retrospective studies have
suggested that HER2+ tumors may be less sensitive to
endocrine treatments [28,32]. In our study, a clear and
strong negative association between HER2 and HR in
Table 2 Cox proportional hazards regression analysis for
survival
Factors Sig. (P value) Relative risk 95.0% CI for
relative risk
Age 0.097 1.023 0.996-1.052
Tumor size 0.172 1.789 0.777-4.121
Tumor type 0.594 1.315 0.480-3.604
Histological grade 0.443 1.323 0.647-2.702
Lymph node status 0.352 1.379 0.701-2.712
TNM stage 0.794 1.095 0.554-2.162
SATB1 0.014 2.413 1.197-4.846
HER2 0.024 2.089 1.100-3.969
HR 0.004 0.397 0.213-0.741
Liu et al. Diagnostic Pathology  (2015) 10:50 Page 8 of 9breast cancer was observed. Namely, HR usually negative
expressed while HER2 overexpressed in breast cancer,
which was in keep with previous studies [10,16]. The in-
verse association between HER2 and HR levels in clinical
specimens is in sympathy with cell line data in a prior
study by Pietras [33]. In their study, they introduced
HER2 cDNA into MCF7 (which is HER2 low and ER posi-
tive cell line) and discovered the transcripts and protein
suppression of ER in the transfected cells [33]. This might
explain the phenomenon that HER2 amplification/overex-
pression is consistent with negative HR status. Not only
decreasing ER expression, HER2 usually induces the fail-
ure of endocrine treatment, such as tamoxifen therapy. In
our study, a significantly negative association between
SATB1 and HR was also found. Furthermore, the inverse
relevance was observed between the co-expression of
SATB1/HER2 and HR expression in breast cancer pa-
tients. HER2 could regulate ER expression and play a role
in the resistance to hormonal, chemo- and radiotherapy
[32]. Kobierzycki et al. found a moderate positive correl-
ation between Ki-67 and SATB1 expression and the cor-
relation was even obvious in ER-negative patients (r =
0.291, p = 0.045 independently on the receptor status, and
r = 0.392, p = 0.032 in ER-negative tumors) [34], which in-
dicates an indirect role of SATB1 in the cancer cell prolif-
eration. SATB1 could upregulate gene expressions which
are associated with tumor cell resistance to apoptosis and
multidrug treatment, such as BCL2 and MDR [1,19]. In
vitro studies have demonstrated that elevated expression
of SATB1 contributes to maintenance of the malignant
phenotype and resistance to chemotherapeutic drugs in
many other cancers [35,36]. Collectively, SATB1 might in-
hibit HR expression in cooperate with HER2 and pro-
motes tumor progression or estrogen therapy resistance in
breast cancer.
Previous data indicated that HER2 was amplified more
commonly in higher histological grade than lower grade
in breast cancer [8,16,18]. Similar to these studies, ourresults showed that HER2 was associated with advanced
histological grade in breast cancer. Han et al. [3] reported
that SATB1 expression was significantly higher in poorly
differentiated tissues. Patani et al. [2] detected SATB1
mRNA increased in high histological grade breast cancer.
Accordingly, we also found there was significant correl-
ation between SATB1 and breast cancer histological grade.
Moreover, co-expression of SATB1 and HER2 was signifi-
cantly associated with advanced tumor histological grade
in breast cancer patients. Histological grade was an im-
portant index of poor differentiation in breast cancer. Our
results suggested that HER2+, SATB1+ and SATB1/HER2
co-expression associated with high degree of malignancy
in breast cancer. They may play an important role to pro-
mote cancer cell proliferation and differentiation. How-
ever, no association was observed between HR expression
and tumor histological grade. Kaplan–Meier survival ana-
lyses demonstrated that SATB1/HER2 single positive and
co-expression patients inclined to have poor prognosis,
whereas HR positive expression tended to get preferable
outcome. Cox regression analyses elucidated that SATB1
and HER2 were independent risk factors for patients’ sur-
vival in breast cancer and HR was a protective factor.
Based on the results above, the expression of HER2
had synergistic effect with SATB1 in breast cancer and
HR had reverse influence compared to SATB1 and
HER2. There might be intrinsic linkage among SATB1,
HER2 and HR. Further researches are needed to ex-
pound the elaborate mechanism of the crosstalk and
regulatory network among SATB1, HER2 and HR.
In conclusion, this study has reported on the relation-
ships between SATB1, HER2, HR expression and clinico-
pathologic characteristics in breast cancer tissues. SATB1+,
HER2+ and SATB1/HER2 co-expression correlated with
higher histological grade and were independent risk factors
of patients’ survival, which suggested that SATB1/HER2
positive expression weighed highly with poorly differenti-
ated breast cancer and HR were protective factors. Further
researches of therapeutics targeting the inner link or cross-
talk among SATB1, HER2 and HR would give maximum
benefits to patients with breast cancer.Competing interests
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